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Abstract
Probiotics are believed to alleviate allergic and inflammatory skin disorders, but their impact on pathogenic effector T cells
remains poorly documented. Here we show that oral treatment with the probiotic bacteria L. casei (DN-114 001) alone
alleviates antigen-specific skin inflammation mediated by either protein-specific CD4
+ T cells or hapten-specific CD8
+ T cells.
In the model of CD8
+ T cell-mediated skin inflammation, which reproduces allergic contact dermatitis in human, inhibition
of skin inflammation by L. casei is not due to impaired priming of hapten-specific IFNc-producing cytolytic CD8
+ effector T
cells. Alternatively, L. casei treatment reduces the recruitment of CD8
+ effector T cells into the skin during the elicitation (i.e.
symptomatic) phase of CHS. Inhibition of skin inflammation by L. casei requires MHC class II-restricted CD4
+ T cells but not
CD1d-restricted NK-T cells. L casei treatment enhanced the frequency of FoxP3
+ Treg in the skin and increased the
production of IL-10 by CD4
+CD25
+ regulatory T cells in skin draining lymph nodes of hapten-sensitized mice. These data
demonstrate that orally administered L. casei (DN-114 001) efficiently alleviate T cell-mediated skin inflammation without
causing immune suppression, via mechanisms that include control of CD8
+ effector T cells and involve regulatory CD4
+ T
cells. L. casei (DN-114 001) may thus represent a probiotic of potential interest for immunomodulation of T cell-mediated
allergic skin diseases in human.
Citation: Hacini-Rachinel F, Gheit H, Le Luduec J-B, Dif F, Nancey S, et al. (2009) Oral Probiotic Control Skin Inflammation by Acting on Both Effector and
Regulatory T Cells. PLoS ONE 4(3): e4903. doi:10.1371/journal.pone.0004903
Editor: Derya Unutmaz, New York University School of Medicine, United States of America
Received January 8, 2009; Accepted February 18, 2009; Published March 20, 2009
Copyright:  2009 Hacini-Rachinel et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by institutional grant from INSERM (infrastructure charges), and from grant from Danone Research Center (Palaiseau, France).
F. Hacini-Rachinel is the recipient of a CIFRE this grant from DANONE. Danone as a private company has no role in study design, data collection or interpretation.
The authors have no financial conflict of interest.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: dominique.kaiserlian@inserm.fr
Introduction
Probiotics are defined by FAO and WHO as live microorgan-
isms which when administered in adequate amounts, confer a
health benefit to the host [1]. Orally administered probiotics
exhibit widespread effects on gut homeostasis and immunomod-
ulation of both mucosal and systemic immunity. Probiotics may
counterweight aggressive enteric commensals in the gut and
reinforce the barrier function of the epithelium but can also
contribute in the regulation of innate and adaptive immune
responses of the host under healthy or pathogenic conditions
(reviewed in [2]). Lactic acid bacteria including bifidobacteria and
lactobacilli used as probiotics are commensal bacteria of the gut
microbiota that could be used for prevention or treatment of
chronic allergic and inflammatory diseases, such as inflammatory
bowel disease (IBD) [3] and atopic dermatitis [4]. Recently, studies
in patients with IBD [5] and in animal models of colitis [6,7]
emphasized that probiotics modulate the outcome and severity of
intestinal inflammation. Oral administration of a probiotic cocktail
(VSL#3) composed of several lactic acid bacteria reduced the
severity of chronic T-cell mediated TNBS induced-colitis in mice
by acting via a subset of TGFß-bearing cells in the gut lamina
propria [6]. In a recently developed mouse model of colitis
mediated by cytotoxic CD8 T cells [8], we observed that L. casei
DN-114 001 exerts a protective effect on the severity of intestinal
lesions and enhances the function of mucosal CD4
+ FoxP3
+ Treg
in the colon lamina propria (Hacini-Rachinel et al, submitted).
Besides immunomodulation on mucosal inflammation, probio-
tic may also regulate systemic immune responses that contribute to
allergic and inflammatory skin diseases. Studies in human have
documented that atopy including atopic dermatitis is less
frequently observed in children from mothers who have been
under a probiotic diet during pregnancy and the post natal period
[9]. The outcome of probiotic treatment on systemic immune
responses involved in chronic inflammatory and allergic diseases is
still poorly documented. Contact dermatitis is one of the most
common skin allergies in western countries [10]. We previously
reported that oral administration of L. casei (strain DN-114 001)-
fermented milk reduces T cell-mediated delayed-type contact
hypersensitivity (CHS) to the hapten 2-4-dinitrofluorobenzene
(DNFB) in normal mice [11], which reproduces the pathophys-
iology of allergic contact dermatitis in human. Moreover, a clinical
study in human with allergic contact dermatitis to Nickel showed
that oral treatment with L. casei-fermented milk reduces the
severity of prurit and itching (Danone patent EP 1 838 158 B1).
However, the impact and mode of action of probiotics, including
L. casei, on immune responses involved in the pathophysiology of
allergic diseases remains elusive.
Development of allergic contact dermatitis to Nickel [12], drugs
(i.e. antibiotics) and contact sensitizing chemicals (i.e. food
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logical phases. The asymptomatic sensitization phase (i.e. the
afferent phase of CHS), which is induced by topical skin exposure
to the hapten, results in the priming of hapten-specific T cells. The
symptomatic phase (i.e. the efferent phase of CHS) is elicited upon
a novel exposure to the same hapten in sensitized individuals and
leads within 24/48 hours to the recruitment of the inflammatory
skin infiltrate and induction of skin lesion. We and others have
extensively characterized the pathophysiology of the CHS
response to DNFB in mice and showed that skin inflammation is
mediated by hapten-specific IFNc-producing Tc1-type CD8
+ T
cells primed within 5 days in skin draining lymph nodes
[13,14,15,16]. These CD8 effectors initiate the inflammatory
process by performing Fas/Fas ligand and perforine-mediated
apoptosis of keratinocytes [17,18]. In vivo priming of CD8 effectors
and development of the CHS response are independent of CD4 T
cell help and the intensity and resolution of skin inflammation is
under control of regulatory CD4 T cells (Treg) [15,19–21]
including CD4
+CD25
+FoxP3
+ Treg [22]. Studies in human with
Nickel allergy have confirmed that skin inflammation is mediated
by Tc1-type CD8 effectors and regulated by CD4
+CD25
+ Treg
[23].
In the present study, using experimental models of DTH
responses mediated by CD4
+ T cells specific to a protein Ag,
ovalbumin) and by CD8
+ T cells specific to the hapten DNFB, we
found that oral administration of live L. casei strain DN-114 001
down-regulate skin inflammation mediated by CD4
+ or CD8
+ T
cells. We demonstrated in the CHS model that L casei does not
impair the priming or differentiation of hapten-specific CD8 T
cells in lymphoid organs, but reduces the frequency of CD8 T cells
recruited into the skin upon elicitation of CHS by hapten
challenge. We show that this effect requires CD4
+ T cells and is
accompanied by an effect of L. casei on the frequency and function
of Treg.
Materials and Methods
Mice
Female C57Bl/6 (2–4 month old) were purchased from Charles
River laboratories (L’Arbresle, France). MHC-class II (Abu/u)-
deficient mice were kindly provided by D. Mathis and C. Benoist,
CD1du/u by L. VanKaer, CD3eu/u by M. Malissen and bred as
homozygotes (C57Bl/6 back-ground, 9
th generation) in our animal
facilities. All mice were bred at the institute’s animal facilities
(Plateau de Biologie Expe ´rimentale de la Souris, Ecole Normale
Superieure de Lyon) under specific pathogen-free conditions. All
experiments were previously approved by the Animal Care and
Use Committee according to governmental guidelines.
Bacteria
L. casei DN-114 001 was grown for 16 h at 37uC under aerobic
conditions in neutral Man-Rogosa-Sharpe liquid medium (MRS
broth, Difco, France). Bacteria were harvested in the stationary
phase of growth and stored at 4uC. Viability of L. casei DN-114
001 was .95% for up to 1 week at 4uC. Just before use, bacteria
were washed twice in 0.9% NaCl and adjusted at 10
8 cfu/ml.
Probiotic treatment
Treatment was started at day –14 before epicutaneous
sensitization with DNFB and continued until the end of the
experiments (i.e. day 12 after sensitization). Mice (5–7 per group)
were fed daily by an intragastric stainless steel feeding tube with
200 ml of either live L. casei DN-114 001 (10
8 cfu/ml), or sterile
0.9% NaCl (control).
Contact hypersensitivity (CHS) to DNFB
Contact sensitivity to DNFB was induced as described [21].
Briefly, mice were sensitized on day 0 by epicutaneous application
onto the shaved abdomen of 25 ml of 0.5% DNFB (Sigma Aldrich,
St. Quentin Fallavier, France) diluted in acetone/olive oil (4:1,
vol/vol) (i.e. vehicle). On day 5, mice were ear challenged with
0.15% DNFB applied onto the right ear; the left ear received the
vehicle alone. Ear thickness was measured with a micrometer (J15
Blet, Lyon, France) before and each day after challenge. Ear
swelling was calculated as the difference of swelling between the
right and the left ear (ear swelling=ear thickness after challenge –
ear thickness before challenge). Results are expressed in mm. Ear
swelling after DNFB challenge in unsensitized mice was routinely
below 20 mm.
Delayed Type Hypersensitivity (DTH) to ovalbumin
Mice were sensitized subcutaneously with 50 mg of OVA (grade
VII, Sigma, France) in 25 ml of saline emulsified with an equal
volume of CFA and injected in both sides of the base of the tail.
Seven days later the DTH response was elicited by sc challenge
with 200 mg of aggregated OVA injected s.c. into the left hind
footpad, while the right hind footpad was injected with saline.
Aggregated OVA was prepared by heating a 2% solution of OVA
at 70uC for 1 h. After cooling, the precipitate was washed and re-
suspended in the original volume of saline. Footpad thickness was
measured at 24 and 48 h after challenge using calipers. Footpad
swelling was determined by subtracting values given by saline-
injected footpads from those of Ag-injected footpads.
Isolation of CD8
+ T cells and CD4
+ CD25
+ T cells
After B cells depletion using columns coated by goat anti-mouse
and anti-rat IgG BioMagH beads (Qiagen, Germany), CD8
+ T
cells from splenic, axillary and inguinal lymph nodes of day 5
hapten-sensitized mice were purified by positive selection using
anti-CD8 mAb-coated microbeads and magnetic columns (Milte-
nyi Biotec, France). CD4
+CD25
+ T cells were purified by positive
selection using anti-CD25 mAb-coated microbeads. The percent-
age of CD8
+ T cells and CD4
+CD25
+ T cells was routinely .90%
and 70% respectively as determined by FACS analysis.
Direct in vivo cytotoxicity assay
In vivo analysis of hapten-specific cytotoxic T cells (CTL) was
assessed on day 5 after immunization, as described [8]. Mice
were injected i.v. with a mixture of target cells including, 10 10
6
DNBS-pulsed and 10 10
6 unpulsed spleen cells, previously
labeled with 0.5 mmol/L and 5 mmol/L of carboxy-fluorescein
succinimidyl ester (CFSE), respectively. 24 hours later, cell
suspensions from pLNs and spleens were prepared and 10,000
CFSE positive cells were acquired by using a FACSCalibur (BD
Biosciences, San Jose ´, CA). In vivo cytotoxicity was assessed by
calculating the ratio of unpulsed/pulsed targets in immunized
versus naive mice.
Extraction of skin cells
Total ear cell suspensions were prepared as previously described
[24]. Ears were split into dorsal and ventral halves, cut in small
pieces and incubated for 90 min at 37uC with 400 U/ml of
collagenase IA (Sigma) and 400 U/ml of DNAse I (Roche
Diagnostics, Germany) in RPMI 1640 supplemented with 10%
FCS, 25 mM Hepes. Cell suspensions were filtered through nylon
mesh (100 mm) washed and resuspended in PBS containing 2%
FCS, 0.5 mM EDTA and 0.01% NaN3 and stained for FACS
analysis.
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Cells were first incubated with 2.4G2 hybridoma supernatant to
block Fcc receptors and then stained with various combinations of
the following anti-mouse antibodies from BD Pharmingen :
allophycocyanin (APC)-conjugated rat anti- CD45 (IgG2b,k; clone
30-F11), peridinin chlorophyll protein-cyanin 5.5 (PerCP-Cy5.5)-
conjugated rat anti-CD8a (IgG2a,k; clone53-6.7), PerCP-conju-
gated rat anti-CD4 (IgG2a,k; clone RM4-5); fluorescein isothio-
cyanate (FITC)-conjugated rat anti-CD25 (IgM; clone 7D4).
Appropriate isotype-matched mAbs were used as control. For
intracellular Granzyme B staining cells were fixed and permea-
bilized with Cyto-fix-Cytoperm (BD, France) and stained with the
mouse anti-human granzyme B-phycoerythrin (PE) (Caltag). Rat
anti-mouse FoxP3 (IgG2a,k; clone FJK-16s) staining was per-
formed according to the manufacturer’ instructions (eBiosciences).
Fluorescence was measured with a FacsCalibur equipped with
CellQuest software (BD, Canada).
CHS response in the T cell transfer model in CD3e KO
mice
CD8
+ T cells (5.10
6) alone or together with CD4
+CD25
+ T cells
(0,5.10
6) from C57Bl/6 14 days were isolated after 14 days oral
treatment with L. Casei and transfered i.v into CD3eu/u mice one
day before skin sensitization with 0,5% DNFB. Mice were ear
challenged 5 days later with 0,14% DNFB and the CHS response
was determined as described above.
IL-10 production
CD4
+ CD25
+ T cells (2. 10
5) from day 5 DNFB-sensitized mice
were cultured for 72 h with soluble 1 mg/ml of anti-mouse CD3
(BD Pharmingen, France) with 10 U/ml of murine IL-2 (Roche
Diagnostics, Germany). Supernatants were titrated for IL-10 using
an ELISA kit (R&D, USA).
Statistical analysis
Statistical analyses were perfomed using th Student’s t-test and
the non-parametric Mann-Whitney two-sample test, using a two-
sided significance level of 5%. P values,0.05 were considered to
be statically significant (*: 0.01 to 0.05, **: 0.001 to 0.01, ***:
,0.001).
Results
Oral L. casei reduces systemic CD4
+ and CD8
+ T cell-
mediated DTH responses
We tested whether oral treatment with L. casei could alleviate
systemic DTH responses mediated by Ag-specific T cells in
C57Bl/6 mice. Mice treated daily by gavage from day –14 with
2.10
7 cfu of live L. casei DN 114001, exhibited a reduced CHS to
DNFB (Fig 1A). L. casei-treatment also decreased the skin DTH
response to OVA as demonstrated by the decreased footpad
swelling reaction (Fig 1B). Thus, oral administration of live L. casei
into normal mice reduces the severity of T cell-mediated DTH
responses mediated by Ag-specific CD4
+ or CD8
+ T cells.
L. casei does not impair in vivo priming of hapten-specific
CD8
+ CTL effectors
We previously documented that hapten-specific IFNc-produc-
ing cytolytic CD8
+ T cells primed in skin draining LN during the
afferent phase of CHS represent the pathogenic effectors of the
CHS response to DNFB [17]. We thus investigated whether L.
casei affected the in vivo priming of Ag-specific CD8
+ T CTL
induced by skin sensitization, using a direct in vivo cytotoxic assay.
Mice were injected on day 5 after sensitization with a mixture of
hapten-pulsed and unpulsed target cells labeled with a low and
high concentration of the fluorescent marker CFSE, respectively
and their fate in lymphoid organs was analyzed the next day by
flow cytometry. As shown in Fig 2, control NaCl-treated and L.
casei-treated mice exhibited on day 5 after sensitization a similar
DNFB-specific CTL activity in skin draining LN (NaCl treated:
75.23%69.86; L. casei treated group: 75.22%611.28) and spleen
(NaCl treated: 53.38%612.81; L. casei treated group:
50.26%610.37). Thus, L. casei oral administration did not impair
the in vivo priming and differentiation of hapten-specific specific
CD8
+ T cells into functional cytolytic CHS effectors in skin
draining LN during the afferent phase of CHS.
Figure 1. Immunomodulatory effect of L. casei on DTH responses. C57Bl/6 mice were treated daily with either live L. casei (black circle) or
physiologic water (white circle) from day –14 before sensitization until the end of the experiment. (A) CHS to DNFB was induced by skin painting on
day 0 with 0.5% DNFB and ear challenge on day 5 with 0.15% DNFB (right ear) or the vehicle alone (left ear). The CHS response was determined by ear
swelling at various time points after challenge, as described in Material and Methods. The dotted line represents ear swelling after ear painting with
0.15% DNFB in unsensitized mice. (B) DTH to OVA was induced by subcutaneous injection on day 0 with 50 mg OVA mixed with CFA and footpad
challenge 7 days later with either 250 mg aggregated ovalbumin (right footpad) or physiologic water (left footpad). The DTH response was
determined by footpad swelling at various time points after challenge, as described in Material and methods. The dotted line represents foodpad
swelling after footpad challenge with OVA in mice immunized with CFA alone. Results are expressed as mean6SD of swelling for 7–10 mice per
group. Data are representative of three to ten experiments. p values were performed using the Mann-Whitney two-sample and Student’s t-tests.
doi:10.1371/journal.pone.0004903.g001
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+ CHS effectors into
the skin
The efferent symptomatic phase of the CHS response induced
upon challenge is initiated by the recruitment into the challenged
skin site of primed CD8
+ T cells, which initiate skin inflammation
by inducing apoptosis of ke ´ratinocytes [17,18]. We thus examined
the outcome of L. casei treatment on the number and kinetics of
accumulation of cytolytic granzyme B
+ CD8
+ effectors into the
skin, at various time after hapten challenge. Irrespectively of L.
casei treatment, CD8
+ T cells were hardly detectable in the skin of
NaCl-treated control unsensitized mice at 48 h post ear challenge
(Fig 3A and B, left panels). Ear challenge of sensitized mice with
the hapten resulted in the rapid recruitment of CD8
+ T cells
including both granzyme B
+ and granzyme B
2 CD8
+ CTL, which
appeared within 24 hr after challenge and persisted for up to 72 hr
(Fig 3A upper right panel, and Fig 3B left). Interestingly, both
granzyme B
+ and granzyme B
2 subsets of CD8
+ T cells were
decreased in L. casei-treated mice (Fig 3A lower right panel, Fig 3B
right).
L. casei impairs the efficacy of naive CD8
+ T cells to
induce CHS
We recently reported that orally-induced tolerance of CD8
+ T
cell-mediated CHS to DNFB is initiated by a mucosal step of in vivo
CD8
+ T cell hyporesponsiveness, which impairs further differen-
tiation of CD8
+ T cells into CHS effectors [25]. To determine
whether oral administration of L. casei could induce a similar
conditioning of naive CD8
+ T cells in lymphoid organs, we set up
a model of CHS induced by adoptive transfer of CD8
+ T cells into
T cell deficient CD3eu/u mice. MACS-sorted CD8
+ T cells from
naive C57Bl/6 donor mice that were treated daily for 14 days by
oral administration of L. casei or NaCl, were transferred i.v. into
naive syngenic CD3eu/u recipients and the CHS response to
DNFB was examined in the recipients (Fig 4A). As expected, un-
reconstituted CD3eu/u recipient mice were unable to mount a
CHS response while reconstitution with CD8
+ T cells from control
NaCl treated donors induced a potent CHS response (mean ear
swelling 237 mm671). In contrast, skin inflammation in recipients
of CD8
+ T cells from L. casei treated donors, was significantly
reduced (mean ear swelling 173.8 mm618, Fig 4B). Thus, naive
CD8
+ T cells from systemic lymphoid organs conditioned by oral
L casei in vivo, exhibited impaired ability to induce a CHS response
in vivo.
L. casei inhibition of CHS requires MHC class II-restricted
CD4
+ T cells but not CD1d-restricted NK-T cells
CD4
+ T cells are dispensable for the priming of CD8
+ T cells
mediating DNFB-specific CHS response, but contain regulatory T
cells including MHC class II-restricted CD4
+CD25
+ Treg, which
control skin inflammation [15,16,19,21] and CD1d-restricted NK-
T cells, which contribute to oral tolerance [26]. To determine
whether L. casei inhibition of the CHS required regulatory T cells,
we tested the outcome of oral L. casei treatment on CHS to DNFB
in Aßu/u mice (deficient in MHC class-II restricted CD4
+ T cells)
and in CD1du/u (deficient in NK-T cells). While L. casei treatment
was able to reduce the intensity of the CHS response in CD1du/u
mice (Fig 5A) similarly than in wild type C57Bl/6 mice (Fig 1A), it
was unable to control the hapten-specific skin inflammation in
Aßu/u mice, (Fig 5B), indicating that regulation of DTH responses
by L. casei depended on class II-restricted CD4
+ Tregs but not on
NK-T cells.
L. casei treatment does not affect the in vivo suppressive
function of nTregs in lymphoid organs of naive mice
To determine whether L. casei treatment affected the pool of
natural CD4
+CD25
+ Tregs of lymphoid organs at the steady state
(i.e. unsentitized mice), we set up an adoptive co-transfer model of
CD4
+CD25
+ Tregs and CD8
+ T cell into T cell deficient CD3eu/u
mice. MACS-sorted CD4
+CD25
+ T cells harvested from naive
C57Bl/6 donor mice treated by daily oral administration of L. casei
or NaCl as control for 14 days, were co-transferred with CD8
+ T
cells from naive C57Bl/6 into syngenic CD3eu/u recipients one
day before skin sensitization and the CHS response to DNFB was
examined after ear challenge with DNFB (Fig 6A). As described
above (Fig 4B), CD3eu/u recipient mice mounted a CHS response
to DNFB only upon CD8 reconstitution, with a mean ear swelling
of 330 mm685 at day 4 after challenge, that was sustained for up
to day 9 (Fig 6B). Co-transfer of Tregs cells from either NaCl- or
L. casei- treated donors resulted in a similar 30% (p=0.0076)
reduction of skin inflammation with mean ear swelling values at
96 hr post challenge of 220 mm692 and 230 mm657, respective-
ly. These data demonstrate that daily oral exposure to L. casei in a
naive host is not capable to affect the potential of natural CD4
+
CD25
+ Treg of lymphoid organs to suppress a CHS response.
L casei affects the frequency of CD4
+FoxP3
+Treg in the
skin
Analysis of the frequency of Tregs in the skin cells was carried
out in naive mice as well as after DNFB challenge of sensitized
C57Bl/6 mice. At 48 hr post hapten skin challenge, control
unsensitized mice exhibited a high proportion of FoxP3
+CD4
+ T
cells (i.e. 42% of total CD4
+ T cells), among which roughly 2/3
expressed the CD25 molecule (Fig 3C, upper left); sensitization did
not affect the frequency of FoxP3
+CD4
+ Treg present in the skin
at 48 hr after challenge (Fig 3C, upper right). Alternatively, L. casei
treatment increased the frequency of skin resident
CD4
+CD25
+FoxP3
+ Tregs in control unsensitized mice, to a level
that was maintained up to 48 hr post challenge in sensitized mice
Figure 2. Effect of L. casei on hapten-specific CD8
+ CTL in vivo.
Hapten-specific in vivo CTL assay was carried out in mice treated daily
from day -14 with either NaCl (white bars) or L. casei (black bars). Mice
were sensitized on day 0 with 0.5% DNFB and 5 days later were injected
intravenously with a 1:1 mixture of DNBS-pulsed and unpulsed spleen
cells as target cells, stained with 0.5 mmol/L and 5 mmol/L of CFSE,
respectively. Twenty-four hours later, the percentage of stained cells in
pooled pLN and spleen was analyzed by FACS. In vivo cytotoxicity was
calculated by determining the ratio of control targets/pulsed targets.
Results are expressed as mean6SD of the percentage of hapten-specific
cytotoxicity.
doi:10.1371/journal.pone.0004903.g002
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inhibition of the CHS response in L. casei-treated mice, as
confirmed in the same experiment (Fig 3D).
L. casei treatment increases IL-10 production by Tregs in
sensitized mice
We next asked whether L. casei treatment could have effect on
antigen experienced- CD4
+CD25
+ Tregs. To test this hypothesis,
CD4
+CD25
+ T cells were isolated from L. casei- or NaCl-treated
mice on day 5 after DNFB sensitization and tested ex-vivo for IL-10
production in response to in vitro stimulation with anti-CD3 mAb
with IL-2. CD4
+CD25
+ T cells from NaCl-treated DNFB-
sensitized mice produced IL-10 upon polyclonal in vitro stimulation
with anti-CD3 and treatment with L. casei did not affect percentage
of CD4
+CD25
+ cells of either naı ¨ve (not shown) or day 5-sensitized
(Fig 7A) C57Bl/6 mice. However, L. casei treatment resulted in a 3
fold increase in IL-10 production by CD4
+CD25
+ T cells from
sensitized mice, in response to ex vivo stimulation with anti-
CD3+IL-2 (Fig 7B). These data indicate that L. casei treatment is
capable to promote the activation of Ag-experienced CD4
+CD25
+
Tregs and increases their ability to produce IL-10.
Discussion
Our data demonstrate that oral administration of L. casei DN-
114 001 is able to alleviate skin DTH responses mediated by Ag-
specific CD4
+ or CD8
+ T cells. This is reminiscent of recent
studies showing that lactic acid bacteria decrease the Th1-type
CD4 responses to type II collagen in a mouse model of arthritis
Figure 3. Effect of L. casei on CD8
+ effectors and FoxP3
+ regulatory T cells in the skin. Total cells were extracted from ears of either L. casei
treated or NaCl mice that were either unsensitized, or DNFB-sensitized and harvested at 24 h, 48 h and 72 h post DNFB ear challenge. (A) Dot plot
FACS analysis on gated CD45
+ cells of ear cell suspensions staining for CD8 and granzyme B at 48 hr post challenge. (B) Histograms representation of
the percentage of granzyme B
+ CD8
+ T cells (black portion) and granzyme B
2 CD8
+: white portion) among gated CD45
+ leucocytes from NaCl- (left)
and L. Casei (right) treated mice at various time point after ear challenge. (C) Dot plot FACS analysis of gated CD45
+6CD4
+ T cells after ear cell
suspensions stained for CD4, CD25 and FoxP3 at 48 hr post DNFB challenge in naı ¨ve (left) or sensitized (right) mice, treated with NaCl (top) or L. Casei
(bottom). (D) Corresponding ear swelling at 24 h, 48 h and 72 h post- DNFB challenge in DNFB sensitized mice, treated with NaCl (white circles) or L.
casei (black circles).
doi:10.1371/journal.pone.0004903.g003
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that preventive oral treatment with L. casei alleviates skin
inflammation. L. casei treatment affected only on the symptom-
atic phase of the disease, induced shortly after challenge by the
recruitment of pathogenic CD8 CTL at the site of hapten
challenge [15,17]. Indeed, L. casei did not impair the in vivo
priming and differentiation of hapten-specific cytolytic CD8
+
CHS effectors during the afferent phase induced by skin
sensitization with DNFB. These data thus emphasized that
anti-inflammatory effect of L. casei on skin inflammation does not
merely result from an immunosuppressive effect on T cells.
Alternatively, L. casei decreased the recruitment of pathogenic
CD8
+ effectors into the skin at the site of challenge. We
previously reported that the cytolytic function of CD8
+ Tc e l l s
via the perforin and Fas/Fas-L pathways is crucial to the
initiation of skin lesions of ACD [17]. The fact that both
Granzyme B-expressing and Granzyme B negative CD8
+ Tc e l l s
recruitment into the challenged skin was inhibited in L. casei-
treated mice indicated that the probiotic affected the mobiliza-
tion of both CTL effectors and non cytolytic activated CD8
+ T
cells. Along these lines, CD8
+ T cells from L. casei- treated but
unsensitized mice have a reduced capacity to generate a CHS
Figure 4. CD8
+ T cells from L. casei-treated mice generate a weak CHS in CD3eu/u recipients. (A) Naı ¨ve C57Bl/6 were treated daily for 2
weeks with either L. casei or NaCl 0.9%. On Day -1, pooled CD8
+ T cells (10.10
6) from pLN, mLN and spleens from each group of mice were transferred
i.v. to naive CD3eu/u recipient mice. On day 0 all CD3eu/u recipients were DNFB sensitized and ear challenged with DNFB on Day 5. (B) Ear swelling at
48 h after DNFB-challenge was determined in CD3eu/u recipients transferred with CD8
+ T cells from either L. casei-treated (black circle) or NaCl-treated
(white circle) C57Bl/6 donors as well as in untransferred control CD3eu/u mice (white losange).
doi:10.1371/journal.pone.0004903.g004
Figure 5. Inhibition of CHS by L. casei requires CD4
+ T cells. Abu/u mice (A) and CD1du/u mice (B) were treated daily from Day-14 before DNFB
skin sensitization (Day 0) until the end of experiment with either live L. casei (black circle) or NaCl (white circle). All mice were sensitized on day 0 with
DNFB and ear challenged on day 5 with DNFB. The CHS response was determined by ear swelling (mm) as indicated in Fig. 1 legend. Statistics (p
values) were performed using the Mann Whitney two-sample and Student’s t-test. Dotted lines represent ear swelling values after ear challenge of
unsensitized mice.
doi:10.1371/journal.pone.0004903.g005
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deficient recipient although the same frequency of hapten-
specific IFNc producing cells were generated in the recipients
(not shown). This underscores the intriguing possibility that oral
exposure to L. casei has an impact on the pool of naive hapten-
reactive CD8
+ T cells in lymphoid organs that conditions their
subsequent ability to differentiate into CHS effectors. This
observation is reminiscent to our recent finding that orally
induced tolerance of CHS to DNFB, is initiated by a mucosal
step of hapten presentation by plasmacytoid DC in liver and
MLN, which induces partial deletion of hapten-specific CD8 T
cells [25]. It is possible that CD8
+ T cell conditioning by oral
exposure to L. casei is mediated via pDC, inasmuch as these cells
a r ea b l et on e g a t i v e l yc o n t r o lt h eC H Sr e s p o n s e( personnal data).
Alternatively, L. casei may affect the homing potential of CD8
+ T
cells into inflamed tissues. Indeed, several chemokines are
implicated in CD8
+ T cell recruitment during the CHS response
[28]. In this respect, up-regulation of CCL5/RANTES on CD8
+
T cells from DNFB sensitized mice was shown to contribute to
the recruitment of additional bystander CD8
+ Tc e l l s[ 2 8 ] .I t
may thus be hypothesized that L. casei controls the ability of CD8
to produce or respond to CCL5/RANTES.
The observation that L. casei’s inhibitory effect on the CHS
response depends on the presence of MHC class-II restricted
CD4
+ T cells indicates that L. casei may also affect the capacity
of Treg to control the CHS response. We and others have
demonstrated that Treg including CD4
+CD25
+ natural Tregs
control the in vivo priming of the hapten-specific CD8
+ effectors
in lymphoid organs [15,16]. In addition, Tregs are recruited
into the inflamed skin as CD4
+FoxP3
+ T cells that acquire the
Figure 6. In vivo suppressive function of CD4
+CD25
+ Tregs from L. casei-treated mice. (A) Naı ¨ve C57Bl/6 were treated daily from d-14 to d-1
with either L. casei or NaCl. On d-1, CD4
+ CD25
+ T cells were purified from pooled pLN, mLN and spleens of each group of mice and transferred i.v
together with naive purified CD8
+ T cells into naive CD3eu/u recipients. On day 0, untransferred and transferred CD3eu/u recipients were DNFB-
sensitized and challenged 5 days later with DNFB, as described in Fig 1 legend. (B) Ear swelling was determined at various time after challenge in
CD3eu/u that were either untransferred (dotted lines) or transferred with CD8
+ T cells alone (white squares), or with CD8
+ T cells together with
CD4
+CD25
+ T cells from L. casei- treated (black circle) or NaCl-treated (empty circles) donors.
doi:10.1371/journal.pone.0004903.g006
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that splenic CD4
+CD25
+ Tc e l l sf r o mL. casei-treated and DNFB
sensitized mice exhibit a higher capacity to produce IL-10,
indicating that the probiotic may activate Ag-induced Tregs
in lymphoid organs. In addition, we observed an increased
number of CD4
+CD25
+FoxP3
+ Tregs in the skin of naive L.
casei-treated mice. Since Treg have be shown to suppress CHS
by blocking influx of effector CD8
+ T cells into inflamed tissue
[29], these data suggest that L. casei may promote the homing
and/or the conversion of nTregs in normal skin. To ask whether
L. casei c o u l db ea b l et op r o m o t ede novo conversion of nTreg in
vivo, we performed an adoptive transfer experiment by injecting
Foxp3-eGFP negative CD4
+ T cells from Foxp3-egfp transgenic
mice into RAG2u/u recipient mice, that were subsequently
treated or not with L. casei for 3 months. Although, neoconver-
sion of Foxp3
+ nTreg was observed in the mesenteric lymph
nodes and intestinal lamina propria, and to a much lesser degree
in systemic lymphoid organs, similar neoconversion occurred
irrespective of oral exposure of recipients to L. casei (not shown).
Thus it appears unlikely that at the steady state, the probiotic
could have induced de novo generation of nTreg in the skin. So
far we don’t know how oral gavage with a probiotic can affect
Treg in skin at the homeostatic state, i.e. in the absence of
inflammatory signal. It is possible that components of the
probiotics, (such as nucleic acid or peptidoglycans) may enter
the intestinal lamina propria, circulate via blood and reach
peripheral non mucosal tissues such as the skin. There, they
could act directly or indirectly by enhancing the survival and/or
proliferation of resident Treg possibly via binding to Toll-like
receptors[30] or other commensal sensoring receptors. Another
possibility would be that probiotic components circulating via
the blood may reach lymphoid organs and condition DC/T cell
interactions leading to enhanced expression of skin homing
receptors on T cells.
How oral administration of probiotic bacteria can affect T cell
mediated inflammation in remote skin tissue remains unclear.
Studies have shown that lactic acid bacteria can reduce intestinal
inflammation in IL-10u/u and TNBS models of colitis even when
administered by the parenteral and the subcutaneous routes,
respectively [7,31]. It is possible that components of the bacteria
circulating via the blood flow or via lymph may reach gut-draining
and non draining lymphoid organs [32], exert their effect on Ag-
presenting DC [33,34]. In this respect, recent studies showed that
DC pre-incubated with lactic acid bacteria can alleviate colitis as
efficiently as after systemic delivery of the probiotic [7]. Moreover,
L. casei was shown to promote the ability of DC to expand T cells
with suppressive function[35]. Whether L. casei may use DC to
behave as biological adjuvants for distinct subsets of Treg,
including Foxp3
+ nTreg or Ag-induced Treg and whether this
probiotic may act by promoting their expansion, survival and/or
homing properties remains an important issue to be further
elucidated.
Taken together our results show that L. casei DN-114001
administered orally is able to alleviate allergic skin inflammation,
without causing immuno-suppression, but via mechanisms that
include control the pathogenic function of CD8
+ T cells and
require Tregs.
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